Trial Profile

A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Seasonal-influenza-virus-vaccine-high-dose+COVID-19-Vaccine-adjuvanted-Sanofi (Primary)
Indications Influenza virus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Sanofi

28 May 2025 Planned End Date changed from 3 Apr 2025 to 3 Apr 2026.
28 May 2025 Planned primary completion date changed from 3 Apr 2025 to 3 Apr 2026.
03 Apr 2025 Planned End Date changed from 24 Feb 2026 to 3 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com